Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial

Circulation

Volumn 122, Issue 17, 2010, Pages 1716-1724

  Ensrud, Kristine ^a,b   Lacroix, Andrea ^c   Thompson, John R ^d   Thompson, David D ^d   Eastell, Richard ^e   Reid, David M ^f   Vukicevic, Slobodan ^g   Cauley, Jane ^h   Barrett Connor, Elizabeth ⁱ   Armstrong, Roisin ^d   Welty, Francine ^j   Cummings, Steven ^k  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Pfizer Global Research and Development   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g UNIVERSITY OF ZAGREB   (Croatia)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HARVARD UNIVERSITY   (United States)

^k CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

more..

Author keywords

clinical trial; coronary heart disease; selective estrogen receptor modulator; stroke

Indexed keywords

CALCIUM; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LASOFOXIFENE; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; STROKE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PYRROLIDINES; RECEPTORS, ESTROGEN; RISK FACTORS; STROKE; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 78149283316     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.924571     Document Type: Article

References (21)

1. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629.
2. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860-864.
3. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
4. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
5. McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13:377-386.
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
7. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
8. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
9. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
10. Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63:1230-1233.
11. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686-696.
12. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
13. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937-947.
14. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151:703-715.
15. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191-3195.
16. Davidson M, Welty F, McKenney J. Lasofoxifene has favorable effects on CV biomarkers in postmenopausal women [abstract]. Menopause. 2005;12:787.
17. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri MT, Mariette F, Lien EA, Decensi A. Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. J Thromb Haemost. 2003;1:2149-2152.
18. Blum A, Schenke WH, Hathaway L, Mincemoyer R, Csako G, Waclawiw MA, Cannon RO III. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol. 2000;86:892-895.
19. Collins P, Mosca L, Geiger MJ, Grady D, Kornitzer M, Amewou-Atisso MG, Effron MB, Dowsett SA, Barrett-Connor E, Wenger NK. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation. 2009;119:922-930.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.